News and Trends 31 Jan 2023
BiVictriX announces positive data from leukemia study
BiVictriX Therapeutics plc has announced positive in vivo data from a toxicity evaluation study with BVX001, the company’s lead program, compared to gemtuzumab ozogamicin (GO). GO, marketed as Mylotarg, is…